Compared with the HFD group, all AAJ-treated groups presented significantly higher levels of SOD, CAT, T-AOC, anti-superoxide radical capacity, hydroxyl radical inhibition capacity, and DPPH antioxidant capacity, as well as significantly lower levels of MDA, suggesting that all AAJ products could improve the liver anti-oxidant capacity of dyslipidemia rats (Figure 5). The gene discussed is SOD1; the disease is metabolic syndrome.